Results Up to 4 Years From the OSLER-1 Extension Study on Evolocumab for Hypercholesterolemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Cardiology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
JAMA Cardiol 2017 Mar 14;[EPub Ahead of Print], MJ Koren, MS Sabatine, RP Giugliano, G Langslet, SD Wiviott, H Kassahun, A Ruzza, Y Ma, R Somaratne, FJ RaalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.